



The
Patent
Office

09 / 554547

PCT/GB 98 / 03397

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

REC'D 27 NOV 1998

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

BEST AVAILABLE COPY

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Andrew Gersey

Dated

18 November 1998

THIS PAGE BLANK (USPTO)

13NOV97 E317143-1 D00019
P01/7700 25.00 - 9723945.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

G21931P

2. Patent application number

(The Patent Office will fill in this part)

12 NOV 1997

9723945.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

NATIONAL ENVIRONMENTAL RESEARCH COUNCIL
POLARIS HOUSE
NORTH STAR AVENUE
SWINDON, SN2 1EU
UNITED KINGOM

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGOM

7321354001

4. Title of the invention

TISSUE CEMENT

5. Name of your agent (if you have one)

~~MERCER, CHRISTOPHER PAUL~~

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

CARPMAELS & RANSFORD
43, BLOOMSBURY SQUARE,
LONDON WC1A 2RA

Patents ADP number (if you know it)

83001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: NO

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 34

Claim(s) 5

Abstract 0

Drawing(s) 11

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Carpmiels & Ransford
Signature

Date 12/11/97

CARPMAELS & RANSFORD

12. Name and daytime telephone number of person to contact in the United Kingdom

C.P. MERCER 0171 242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

TISSUE CEMENT

The present invention relates to tissue cement proteins produced by certain species of blood-feeding ectoparasites.

5 These proteins and compositions comprising these proteins are particularly useful for the temporary or permanent bonding of animal tissues to each other or to other biomaterials. The present invention also relates to the use of tissue cement proteins in the production of vaccines that

10 protect animals against the bite of blood-sucking ectoparasites and the transmission of viruses, bacteria and other pathogens by such ectoparasites.

Cement is produced by many blood-feeding ectoparasites,

15 including certain species of Ixodid ticks. Ixodid (hard) ticks are haematophagous parasites that attach themselves to a vertebrate host by means of a 'cement cone', a product of the type II and type III acini of the tick salivary glands (Kemp et al., 1982; Walker et al., 1985).

20

The cement that forms the cone is a milky-white secretion that is injected into the skin of animals from which these parasites feed. The cement comprises a number of interacting protein and carbohydrate components. The cement spreads into

25 the bite site and over the skin, and, upon hardening, ensures that the mouthparts remain firmly anchored to the host during the feeding period, which typically lasts 4 to 8 days. The cement cone functions additionally as a gasket to prevent leakage of fluids from the bite site during

30 feeding.

The tick cement cone is a layered structure, constructed from 2 major types of cement. The first type of cement is produced just minutes after establishing the bite site and

35 hardens quickly to form the rigid core of the cone. A second type of cement is secreted later, about 24 hours after attachment, and hardens more slowly to form the more flexible 'cortex'. In adult ticks, cement production

typically continues until the 3rd or 4th day after attachment (Kemp et al., 1982; Sonenshine et al., 1991).

5 The tick cement cone appears to be mainly proteinaceous, but also contains some carbohydrate and lipid. An early study found the amino-acid composition of whole cement in *Boophilus microplus* to be rich in glycine, leucine, serine and tyrosine (Kemp et al., 1982). However, the individual proteins comprising the tick cement are very poorly
10 characterised; although the mobility of the component proteins has been shown on SDS-PAGE gels, none have yet been purified.

The process by which the cement components harden is also
15 not understood, although mechanisms similar to the tanning of cuticle and coagulation of haemolymph have been proposed (Kemp et al., 1982; Moorhouse and Tatchell, 1966). At present no direct scientific evidence has been produced to substantiate these theoretical mechanisms.

20 It has been noted that the polypeptides that form the cement cortex appear to be similar to certain structural components of vertebrate skin. Involvement of these vertebrate-like molecules may enable ticks to use host-derived enzymes
25 during the cement hardening process - for example lysyl oxidases which cross-link collagen and elastin (Siegel, 1979) or transglutaminases such as the coagulation factor XIIIa, which is induced during wound healing and cross-links fibronectin, fibrins and collagen (Ichinose et al.,
30 1990). These enzymes may cross-link cortex polypeptides to the extracellular matrix proteins of the skin.

Other enzymes such as phenoloxidases or peroxidases which catalyse the hardening of arthropod extracellular structures
35 (Sugumaran et al., 1992) have been identified in *R. appendiculatus* salivary glands and are therefore likely to play a role in solidifying the cement cone.

The composition of tick cement appears to be similar amongst different ixodid tick species. For example, an antiserum raised against a 90kD salivary protein of the brown ear tick, *Rhipicephalus appendiculatus*, has been shown to
5 recognise polypeptides from the salivary glands and cement proteins of the American dog tick, *Dermacentor variabilis*, the lone star tick, *Amblyomma americanum* and the brown dog tick, *R. sanguineus* (Jaworski et al., 1992).

10 All these tick species are extremely effective as transmitters of disease. For example, *R. appendiculatus* represents a major obstacle to livestock development in several sub-saharan regions. It transmits the protozoan parasite *Theileria parva* which causes the usually fatal East
15 Coast Fever. This disease is often considered the most important disease of cattle (Norval et al., 1992a; Norval et al., 1992b). This tick is also the main vector of the virus causing Nairobi sheep disease, a disabling and often deadly disease in sheep and goats (Davies, 1988). *R. appendiculatus*
20 and other tick pests also cause considerable damage to the skin, thereby affecting the leather industry.

In an effort to combat parasite-transmitted diseases, unpurified cement components have been tested as inducers of
25 host resistance (Brown et al., 1986; Shapiro et al., 1989), but reliable vaccines based on cement proteins have not been successfully developed. Cone proteins would appear to be a reasonable target for a vaccine since the formation of the cone is essential for the tick to attach to the host and
30 feed. However, only some of the cone proteins are antigenic.

There therefore exists a great need for an effective vaccine to combat diseases that are transmitted by blood-feeding ectoparasites. The elucidation of the components of tissue
35 cement produced by these organisms would allow the rational design of such vaccines.

Furthermore, these molecules would prove useful in medicine

as components of tissue cement. Presently available tissue cements are of two types, both of which suffer from significant disadvantages. Acrylic-based glues are extremely strong, yet are also very toxic and can thus only be used in very small quantities in the body. The second type of tissue cement used is non-immunogenic but forms a much less strong bond. Consequently this type of cement is only useful in a small number of surgical procedures. There is thus a great need for a non-immunogenic tissue cement that is capable of bonding mammalian tissue with great strength.

Summary of the invention

According to the present invention there is provided a tissue cement protein having the amino acid sequence shown in Figure 3 or Figure 7 or containing any one of the partial amino acid sequences shown in any one of Figures 2, 4 to 6 and 8, related tissue cement proteins from blood-feeding parasites, preferably ticks, and functional equivalents thereof.

The proteins of the present invention are of two subtypes: group A and group B. Proteins in group A form the cement cone core when secreted in saliva and harden quickly to form a rigid latex-like structure. The proteins in group B form the cortex of the cement cone and harden more slowly. The resulting structure is more flexible. Accordingly, functional equivalents of proteins of either group A or B will possess these activities and properties.

The term "functional equivalents" is used herein to describe those proteins that have an analogous function to tissue cement proteins containing the amino acid sequences identified in any one of Figures 2 to 8.

These proteins may belong to the same protein family as the proteins and partial proteins identified in Figures 2 to 8. By protein family is meant a group of polypeptides that

share a common function and exhibit common sequence homology between motifs present in the polypeptide sequences. By sequence homology is meant that the polypeptide sequences are related by divergence from a common ancestor. In particular, as is discussed in more detail below, the proteins and partial proteins identified herein possess certain sequences in common that are repeated several times throughout the sequence of the protein.

- 10 Preferably, the homology between polypeptide sequences is at least 50% across the whole of the amino acid sequence of the protein. More preferably, the homology is at least 75% across the whole of the amino acid sequence of the protein. Most preferably, homology is greater than 80% across the whole of the protein sequence.

By "analogous function" is meant firstly that the proteins have retained the capacity to form a cement. Such proteins will thus be capable of hardening over a period of time to form a solid mass or glue. Secondly, this term may refer to proteins that are structurally similar to group A or group B proteins and thus contain similar or identical epitopes. These functional equivalents may thus be used as immunogens to develop vaccines directed against blood-feeding parasites, that target members of the tissue cement protein family.

Functional equivalents of tissue cement proteins may include, for example, mutants containing amino acid substitutions, insertions or deletions from the wild type sequence. Functional equivalents with improved function from that of the wild type sequence may also be designed through the systematic or directed mutation of specific residues in the protein sequence. Improvements in function that may be desired will include greater strength of bonding, faster speed of bonding or greater flexibility of the hardened cement.

Functional equivalents of tissue cement proteins or protein fragments may be made more or less immunogenic than the corresponding wild type protein or protein fragment in order to suit a desired application. If the proteins are to be
5 used in surgical procedures as tissue cements then the proteins should ideally be non-immunogenic to evade attack by the immune system. However, if the tissue cement proteins are to be used in a vaccination regime to induce host resistance to parasite proteins, then the proteins may need
10 to be modified so as to enhance their immunogenicity. They will thus be more likely to elicit an immune response in the vaccinated host.

Functional equivalents will include conservative amino acid
15 substitutions that do not affect the function or activity of the protein in an adverse manner from that which is desired. This term is also intended to include natural biological variants (e.g. allelic variants or geographical variations within the species from which the tissue cement proteins are
20 derived).

According to the invention, fragments of tissue cement proteins are also envisioned as functional equivalents. Fragments that have retained those portions of the protein
25 that are responsible for a desired activity may prove ideal in certain applications. For example, short stretches of peptide derived from immunogenic portions of tissue cement proteins will be useful as immunogens. An antibody will normally only recognise an epitope comprising between six
30 and twelve amino acid residues. Such short stretches of polypeptide sequence are simple to produce in large quantities, either synthetically or through recombinant means.

35 The tissue cement proteins of the present invention may function either as a structural component of tissue cement or may possess an enzymatic activity directed against the structural components of the tissue cement.

It is thought that most of the protein and partial protein sequences so far identified and shown in Figures 2 to 8 are structural components of tissue cement. The applicant does, however, not wish to be bound by this theory. For example, the protein sequence identified in Figure 2 appears to contain a signal sequence and its sequence resembles that of keratin, a widely studied structural protein. Similarly, the protein whose sequence is set out in Figure 3 also contains a signal sequence and is glycine and proline rich, like many structural proteins. The cemA protein, whose partial sequence is illustrated in Figure 4, contains a number of repeats and is thus also likely to be a structural component of tissue cement.

The protein of Figure 5 is composed of a number of repeats and resembles collagen in sequence. The encoding cDNA shares sequences in common with glutenin, a known self-assembling protein. It thus seems likely that this protein is capable of self-assembly. The applicant does, however, not wish to be bound by this theory. The possibility that this particular sequence may be involved in self-assembly raises the opportunity of using these motifs to bestow on an unrelated protein the ability to self-assemble.

In common with some of the other proteins illustrated in the accompanying Figures, the protein of Figure 6 contains a number of consensus recognition sites for carbohydrate moieties, in particular glycosaminoglycans.

The protein sequence illustrated in Figure 7 also contains consensus attachment sites for glycosaminoglycan moieties and possesses a putative signal sequence. The amino terminal half of the protein resembles collagen, whilst the carboxy terminal shares more in common with keratin. The protein is glycine-rich and contains several repeats of the motif (C/S)1-4(Y/F) which is also found in structural proteins from the egg shells of certain insects. The tyrosines in

these consensus sequences may be involved in the cross-linking of this protein through the formation of dityrosine bridges by the action of phenoloxidases.

- 5 The sequence of Figure 8 is both glycine and tyrosine rich and resembles a cement protein of the reef-building polychaete *Pragmatopoma californica* (see Figure 9). It is thus likely that this protein is also a structural component of tissue cement. The applicant does, however, not wish to
10 be bound by this theory.

The enzymatic activity that may be possessed by the tissue cement proteins of the present invention may involve the ability to effect such covalent modifications as
15 phosphorylation, glycosylation, reduction or oxidation of other proteins and carbohydrate moieties and may result in the cross-linking of the structural components of the tissue cement. Cross-linking may be either reversible or irreversible and may occur between homologous or
20 heterologous components of the tissue cement. The cross-linking may also occur between tissue cement proteins and non-parasite proteins such as, for example, components of vertebrate tissue.

- 25 The tissue cement proteins of the present invention may be group A proteins. By "group A" is meant that in parasite saliva these proteins form the core of the cement cone. The function of the cone core in parasites is to attach to the skin of a vertebrate host and to form a rigid bond that will
30 not break easily. Accordingly, these proteins form a hard latex-like cement that sets and bonds to the vertebrate skin quickly. Group A proteins are thus ideally suited to applications that require a quick-setting tough bond.

- 35 The tissue cement proteins of the present invention may be group B proteins. By "group B" is meant that in tick saliva these proteins form the cortex of the cement cone. One function of the cortex in parasites is to form a gasket-

like seal around the bite site, to prevent leakage of fluids. A further function of the cortex proteins is to form a flexible hinge so that the parasite will not be easily brushed off its host. Accordingly, group B proteins harden
5 more slowly than group A proteins, but set to form a more flexible, pliant cement. These proteins are thus ideally suited for applications when a more flexible bond is required.

10 Many of the structural tissue cement proteins of the present invention share in common the ability to bind to vertebrate tissue. This binding may be due to an inherent affinity possessed by the protein for certain components of the vertebrate skin, such as collagen. However, an affinity for
15 vertebrate proteins may only manifest itself when in the presence of enzymes whose activity is required in order to generate an association between a tissue cement protein and a component of the skin. This enzymatic activity may be derived from tissue cement proteins themselves or may be
20 provided by enzyme components of the vertebrate skin, such as lysyl oxidases, that cross-link collagen and elastin or transglutaminases, such as the coagulation factor XIIIa, which cross-link fibronectin, fibrins and collagen during many vertebrate healing processes.

25 The tissue cement proteins or their functional equivalents according to the present invention may be derived from any blood-feeding parasite. Preferably, the tissue cement proteins of the present invention are derived from blood-
30 feeding ectoparasites, more preferably ticks. Most preferably, the tissue cement proteins of the present invention are derived from the brown ear tick *Rhipicephalus appendiculatus*.

35 The tissue cement proteins of the present invention may also comprise carbohydrate components. Many tissue cement proteins are in fact glycoproteins, containing carbohydrate attachments covalently bound at various sites in the

protein. The carbohydrate generally will comprise a series of glyucose (monosaccharide) units that commonly occur as an oligosaccharide or fairly small polysaccharide. As has been discussed briefly above, many of the proteins so far
5 identified in ticks possess consensus attachment sites for glycosaminoglycans (glycans containing aminosaccharide residues).

The tissue cement proteins of the invention may be present
10 in the tissue cement as monomers, dimers, tetramers, or as oligomers comprising a number of homologous or heterologous monomers as one unit. This is particularly true of structural tissue cement proteins, which may associate non-covalently as part of the cement hardening process. The
15 applicant does, however, not wish to be bound by this theory.

The tissue cement proteins of the present invention may be purified from cement produced by live parasites. This may be
20 done by treating collected cones with a wash solution such as PBS, a TRIS buffer or non-ionic detergents, for example Tween-20 or Triton. Cement proteins may be prepared through immunoprecipitation using antibodies that are specific for epitopes in the protein sequence. Alternatively, the
25 proteins may be prepared synthetically, or using techniques of genetic engineering. Preferably, the tissue cement proteins of the present invention comprise recombinant polypeptides produced by expression from an encoding nucleic acid.

30 Synthetic molecules designed to mimic the tertiary structure or active site of the tissue cement proteins constitute a further aspect of the invention.

35 A further aspect of the present invention comprises tissue cement proteins that are fused to other molecules such as labels, toxins or bioactive molecules. Particularly suitable candidates for fusion will be reporter molecules such as

luciferase, green fluorescent protein, or horse radish peroxidase. Linker molecules such as streptavidin or biotin may also be used. Additionally, bioactive peptides or polypeptides may be fused to a tissue cement protein. Such
5 molecules may comprise molecules with antiseptic or antibiotic properties, or toxins for targeting to cancer cells.

The proteins may be fused chemically, using methods such as
10 chemical cross-linking. Such methods will be well known to those of skill in the art and may comprise for example, cross-linking of the thiol groups of cysteine residues. Chemical cross-linking will in most instances be used to fuse tissue cement proteins to non-protein molecules, such
15 as labels. The labels may be radiolabels, or labels that can be detected spectroscopically, for example fluorescent or phosphorescent chemical groups.

When it is desired to fuse a tissue cement protein to
20 another protein molecule, the method of choice will often be to fuse the molecules genetically. In order to generate a recombinant fusion protein, the genes or gene portions that encode the proteins or protein fragments of interest are engineered so as to form one contiguous gene arranged so
25 that the codons of the two gene sequences are transcribed in frame.

A tissue cement protein may be fused genetically to any
protein for which the encoding gene sequence is known.
30 Particularly suitable candidates for fusion will be reporter molecules such as luciferase, green fluorescent protein, biotin, streptavidin or horse radish peroxidase. Additionally, toxin peptides or polypeptides may be fused to a tissue cement protein. Antiseptic or antibiotic proteins
35 and peptides may also be fused to the tissue cement proteins of the present invention.

According to a further aspect of the present invention there

is provided a pharmaceutical composition comprising a tissue cement comprising a mixture of group A and group B tissue cement proteins in the absence of other parasite saliva proteins, optionally in the presence of one or more
5 compounds capable of cross-linking said tissue cement proteins, in conjunction with a pharmaceutically-acceptable excipient.

Such a pharmaceutical composition has many applications,
10 particularly in skin surgery and wound healing, for the temporary or permanent bonding of human or animal tissues to each other or to other biomaterials.

Tissue cement has previously been used in surgical
15 procedures to provide adhesion and stability to living tissues to enable the normal processes of healing and repair to take place or to provide a long term bond in situations where normal healing is delayed or unlikely to occur. Tissue cement formed from the proteins of the present invention
20 have several advantages over these conventional tissue cements. For example, these proteins form strong bonds with vertebrate tissues. This makes these proteins ideal for use as components of a tissue cement to bond two tissue surfaces or edges together.

25 Different surgical procedures necessitate the use of tissue cement with different properties. Tissue cement formed from the proteins of the present invention is therefore ideal, since the hardening or elastic properties of the cement may
30 be tailored precisely to provide the particular requirements of the surgical procedure through modification of the relative amounts of group A and group B proteins that the cement comprises. The tissue cement is in this manner extremely versatile.

35 Tissue cement with a high content of group A proteins will generally be useful for procedures that require an extremely tough bond that will not need to flex to any great extent.

A good example of such a bond might be a bond between two bone surfaces or between a bone surface and the surface of an artificial joint. A high group A content tissue cement will also be required when it is necessary that the bond
5 sets quickly.

For procedures such as the bonding of skin lacerations, where a high degree of flexibility is required, a tissue cement will be used that contains a high content of group B
10 proteins. However, group B proteins do bond more slowly, so tissue cement with a high group B content will not generally be used for procedures that require a tough bond to form rapidly. However, this cement may be used in conjunction
15 with other measures, such as surgical staples or group A tissue cement, that can form a quick bond to hold the tissues together while the group B proteins harden.

Pharmaceutical compositions that comprise tissue cement proteins according to the present invention may also contain
20 additional preservatives, or components responsible for the prevention of premature setting. The composition may also comprise a propellant, for instance, if the tissue cement is to be sprayed onto tissue surfaces. Such compounds will be well known to those of skill in the art.

25 One important advantage of the tissue cement proteins of the present invention is that, *in situ* in vertebrate tissue these proteins are non-immunogenic and therefore do not cause inflammation of the tissue. This is particularly
30 relevant when the tissue cement is intended for internal use, for example in the securing of prolapsed organs. Were the tissue cement immunogenic, an immune attack would be directed against the tissue cement, so causing local inflammation, disrupting the cement and preventing the
35 permanent bonding of the tissue.

The current rationale in surgery to overcome immune rejection involves combatting the initial rejection

phenomena until, eventually, the immune system becomes tolerant. For example, after organ transplants, huge combined doses of immunosuppressive agents are initially required that are gradually reduced during treatment until, 5 if the transplant successfully survives for a year or so, very little maintenance immunotherapy is required.

The tissue cement proteins of the present invention can also be used to prevent immune rejection. Aside from their 10 natural non-immunogenicity, another property of the tissue cement proteins of the present invention is that the proteins themselves bind to bioactive proteins in the saliva of an ectoparasite, such as, for example, tick histamine-binding proteins. By doing this, the cement proteins 15 localise the action of the various immunosuppressive molecules produced by the organism. These immunosuppressive compounds alter over time during the course of feeding in order to adapt to the host's rejection response. Hence the cement cone, in effect, is an active local immunosuppressive 20 structure.

The ability to bind to bioactive parasite proteins means that tissue cement comprising tissue cement proteins according to the present invention may be complemented with 25 certain immunosuppressive molecules produced by some parasites. For example, suitable molecules might include vasoactive amine binding molecules that are the subject of co-pending International patent application PCT/GB97/01372. These molecules will bind to the tissue cement, and so 30 provide a local immunosuppressive structure that will disguise any allogeneic or even xenogeneic organ and prevent its rejection.

These properties of the tissue cement proteins of the 35 present invention thus provide an addition to the conventional uses of tissue cement to hold articulated joints to bone or to repair damaged organs. Aside from its use as a non-immunogenic adhesive, tissue cement produced

according to the present invention may be used as an adjunct to organ transplantation to supply and localise immunosuppressive compounds to the locality of the transplant.

5

A further aspect of the present invention is therefore to provide tissue cement with immunosuppressive properties by complementation of the basic cement with one or more tissue cement proteins of the present invention, optionally in
10 conjunction with parasite-derived immunosuppressive compounds.

Other specific applications of tissue cement formed from the tissue cement proteins of the present invention may include,
15 but will not be confined to the following list:

repair of incised surgical wounds in place of conventional closures such as sutures or staples; repair of lacerations such as perineal tears following childbirth or flap lacerations after trauma; the grafting of skin, cultured
20 skin substitutes or biomaterial substitutes to chronic wounds, burns, skin graft donor sites and in reconstructive or cosmetic plastic surgery; the securing of myoplastic flaps; tissue to tissue repair as, for instance, repair of lacerations of the liver or other parenchymatous organs;
25 tissue to tissue anastomosis such as gastrointestinal anastomosis or tissue to biomaterial anastomosis such as vascular repair or anastomosis; tissue to tissue reconstruction such as the securing of prolapsed organs in their anatomical site; tissue to tissue approximation as in
30 pleuro-pleural adhesion following recurrent pneumothorax; as a sclerosant in procedures such as the injection of haemorrhoids; in neurosurgical procedures such as the repair or patching of dura mater with natural or artificial substitutes and the grafting or repair of severed neural
35 tissue; in orthodontic procedures such as the re-implantation of teeth or the reconstruction of the mandibular or maxillary arches using bone chips or materials such as collagen matrices or hydroxyapatite; in orthopaedic

procedures including vertebral fusion, arthrodesis, fixation of fractions and osteotomies and the implantation of prostheses such as hip arthroplasty; in procedures such as rhytidectomy where the use of sutures is undesirable on
5 cosmetic grounds; securing of artificial materials such as MarlexTM mesh in hernioplasty (performed in open operation or endoscopically); repair of friable tissue such as tendon or muscle; as a haemostat on oozing surfaces or in
10 circumstances where haemostasis by conventional means is difficult to secure (for example during endoscopic surgery); for the obliteration of sinuses and fistulae; for sealing perforations of hollow visci such as the stomach or duodenum (either used alone or in conjunction with a tissue or artificial patch.

15

In a still further embodiment of the invention, the use of tissue cement proteins is provided as tools in the study of cement cone assembly and in the development of strategies to prevent cement cone assembly, and thereby inhibit tick
20 attachment and feeding. For example, monoclonal antibodies and engineered vaccines directed against tissue cement proteins could be used to prevent parasite feeding.

Arthropod parasites are sources of infectious disease agents
25 such as tick-borne encephalitis virus, Crimean-Congo haemorrhagic fever virus, Nairobi sheep virus, *Borrelia burgdorferi* (the agent of lyme disease), *Theileria parva* (the agent of East Coast fever) and other injurious effects that have major impacts in human and veterinary medicine.
30 Control of the arthropod parasites--currently--relies primarily on the use of chemicals such as acaricides.

Attempts have been made to use immunological means of control through vaccine technology. Some success has been
35 met in identifying certain protective antigens of arthropod parasites as being potential vaccine candidates, but only a few have as yet come to commercial fruition, most notably for the cattle tick *Boophilus microplus*. Despite these

developments, there is nonetheless a continuing need for arthropod parasite vaccines and in particular for a vaccine which may be used against ticks.

- 5 An alternative vaccine strategy that has until now not been possible is to vaccinate animals using purified antigens. The immune system of the animal thus develops an improved humoral response to these antigenic polypeptides and correspondingly develops resistance against the arthropod
10 parasites themselves.

One disadvantage of using vaccines directed against a specific vector-transmitted disease to control that disease is that a different vaccine is usually required to protect
15 against each disease. Vaccines directed against disease vectors (such as ticks and mosquitoes) have an added advantage in that their effect may control several different infections, as long as these infections are transmitted by only one type of disease vector.

20 The present invention therefore also provides for the use of tissue cement proteins as defined above as immunogens. Accordingly, a further aspect of the present invention comprises a vaccine comprising one or more tissue cement
25 proteins as defined above in an arthropod parasite vaccine and in particular as protective immunogens in the control of diseases caused by infections transmitted by arthropod parasites.

30 The vaccine may be administered singly, or in combination with other immunogens. The vaccine may include adjuvants of the type which are well known in the art, for example, alum. Suitable candidates for vaccination include humans, and domesticated animals such as cattle, goats, sheep, dogs,
35 cats and other mammalia. All these species require protection against arthropod parasites, particularly ticks, and the infections they transmit.

According to a further aspect of the present invention there is provided a nucleic acid molecule encoding a tissue cement protein as defined above, or any functionally equivalent form. The nucleic acid sequences of choice comprise or
5 contain the nucleic acid sequences exhibited in Figures 2 to 8. The skilled man will appreciate that changes may be made at the nucleotide level by addition, substitution, deletion or insertion of one or more nucleotides, which changes may or may not be reflected at the amino acid level, dependent
10 on the degeneracy of the genetic code.

The nucleic acid molecule according to this aspect of the present invention may comprise DNA, RNA or cDNA and may additionally comprise nucleotide analogues in its sequence.
15 Preferably, the nucleic acid comprises DNA, more preferably single or double-stranded cDNA.

Antisense sequences may also be designed with respect to the nucleic acids of this aspect of the invention and in
20 sequence will in whole or in part comprise that of the complementary strand to the coding nucleic acid strand. Oligonucleotides comprising antisense sequences to tissue cement protein genes may be used as diagnostic tools in the detection of organisms or vectors expressing nucleic acids
25 that encode tissue cement proteins. These single-stranded oligonucleotides will comprise lengths of nucleic acid of between 10 and 300 nucleotides, preferably, between 10 and 100 nucleotides, most preferably of between 10 and 30 nucleotides. The oligonucleotides may be labelled in order
30 to aid their detection. Suitable labelling systems are well known in the art.

Methods for screening cDNA libraries for proteins analogous to the tissue cement proteins described herein will be
35 apparent to man of skill in the art. The antisense sequences of this aspect of the invention therefore may not correspond exactly to the complementary strand of the nucleic acid that encodes a tissue cement protein. For example, when using

antisense oligonucleotides as probes in the screening of a cDNA library for proteins analogous to the tissue cement proteins described herein, due to the degeneracy of the genetic code and inter-species sequence divergence, any
5 analogous genes to those described herein are likely to comprise sequences that are significantly different to that of the probe.

Accordingly, antisense sequences for use in accordance with
10 this aspect of the present invention comprise sequences that hybridise under standard conditions to the nucleic acid sequences exhibited in Figures 2 to 8. 'Hybridising sequences' included within the scope of the invention are those binding under standard conditions. As used herein,
15 standard conditions is meant to mean both non-stringent standard hybridisation conditions (6 x ssc/50% formamide at room temperature) with washing under conditions of low stringency (2 x, room temperature, or 2 x ssc, 42°C) or at standard conditions of higher stringency, e.g. 2 x ssc, 65°C
20 (where ssc = 0.15M NaCl, 0.015M sodium citrate, pH 7.2). Preferably standard conditions refers to conditions of high stringency.

A further aspect of the present invention comprises a method
25 of production of a tissue cement protein which method comprises expression from the encoding nucleic acid therefor. Expression may conveniently be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid.

30 Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems. Mammalian cell lines available in the
35 art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells and many others. A common, preferred bacterial host is *E. coli*.

The expression of heterologous polypeptides and polypeptide fragments in prokaryotic cells such as *E. coli* is well established in the art; see for example *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Expression in eukaryotic cells in culture is also an option available to those skilled in the art for the production of heterologous proteins; see recent reviews, for example O'Reilly et al., (1994) *Baculovirus expression vectors - a laboratory manual* Oxford University Press.

Suitable vectors can be chosen or constructed for expression of tissue cement proteins, containing the appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. bacteriophage, or phagemid, as appropriate. For further details see *Molecular Cloning: a Laboratory Manual*. Many known techniques and protocols for manipulation of nucleic acid, for example, in the preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Short Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. For example, in eukaryotic cells, the vectors of choice are virus-based, such as the baculovirus.

A further aspect of the present invention provides a host cell containing a nucleic acid encoding a tissue cement protein or functional equivalent thereof. A still further aspect provides a method comprising introducing such nucleic acid into a host cell or organism. Introduction of nucleic acid may employ any available technique. In eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection or transduction using retrovirus or

other viruses, such as vaccinia or, for insect cells, baculovirus. In bacterial cells, suitable techniques may include calcium chloride transformation, electroporation or transfection using bacteriophage.

5

Introduction of the nucleic acid may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene.

10

In one embodiment, the nucleic acid of the invention is integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques.

15

Transgenic animals transformed so as to express or overexpress in the germ line one or more tissue cement proteins or functional equivalents as described herein form a still further aspect of the invention, along with methods for their production. Many techniques now exist to introduce transgenes into the embryo or germ line of an organism, such as for example, illustrated in Watson et al., (1994) Recombinant DNA (2nd edition), Scientific American Books.

25

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to tissue cement proteins isolated from ticks, and especially from *Rhipicephalus appendiculatus*. It will be appreciated that modification of detail may be made without departing from the scope of the invention.

30

Brief description of the Figures

Figure 1A is an SDS-gel containing male and female salivary gland extract (SGE) and male and female cement polypeptides obtained by rinsing cement cones in PBS.

35

Figure 1B is the corresponding Western blot to Figure 1A, probed with a polyclonal antiserum raised against a 17 Kd protein purified from tick salivary gland extract.

- 5 Figure 2 is a partial cDNA sequence and translation product of clone 21. The cDNA-inferred protein is a cement protein; it contains a hydrophobic N-terminal region which possibly constitutes a signal sequence, typical for secreted proteins. The protein strongly resembles other structural
10 proteins, especially keratin. A recognition sequence for post-translational attachment of glycosaminoglycan groups is underlined.

- Figure 3 is a cDNA and cDNA-inferred polypeptide sequence of
15 clone 33. A putative signal sequence is given in bold. Like many structural proteins, this protein is glycine- and proline-rich. The protein also displays some resemblance to keratins.

- 20 Figure 4 is a partial sequence of the *cema* cDNA and the cDNA-inferred polypeptide sequence. The protein is very repetitive, with the sequence KGALLQQQQASQVKGALKAI, or slight variants thereof, repeated several times.

- 25 Figure 5 is a partial cDNA and cDNA-inferred polypeptide sequence of clone 24. The protein has resemblance to structural proteins (amongst others collagen), and is contains repeats. The cDNA has also got a region in common with glutenin, a self-assembling protein.

- 30
Figure 6 is a partial cDNA and cDNA-inferred sequence of clone 68, one of a family of clones identified. The encoded proteins resemble structural proteins, such as keratin. A series of putative glycosaminoglycan attachment sites are
35 underlined.

Figure 7 is a complete cDNA sequence and cDNA-inferred polypeptide sequence of clone 64. The putative signal

sequence is give in bold. A possible glycosaminoglycan attachment site is underlined. The first 40 amino-acid section of the mature protein is collagen-like, whilst the remainder of the sequence resembles keratin. The protein is
 5 glycine-rich and contains several repeats of the motif (C/S)1-4(Y/F), which is also found in structural proteins from insect egg shells. The tyrosines may be involved in cross-linking by formation of dityrosine-bridges by phenoloxidases. A similar protein is encoded by clone I (see
 10 Figure 8).

Figure 8 is an incomplete cDNA-sequence and cDNA-inferred polypeptide sequence of clone I. The inferred protein is glycine- and tyrosine-rich and resembles a cement protein of
 15 the reef-building polychaete *Pragmatopoma californica* (a component of the quinone-tanned cement in the tubes built by these marine worms).

Figure 9 is a DNA alignment between the protein sequence
 20 shown in Figure 8 and a cement protein from the polychaete *Pragmatopoma californica*.

EXAMPLES

25 Ticks

Ticks were reared according to Jones et al., (1988). All three developmental stages of *Rhipicephalus appendiculatus* were fed on Dunkin Hartley guinea pigs. When not feeding, all-ticks were maintained at 21 - 26°C and at 85% relative
 30 humidity.

Example 1 : Identification of proteins

Cement cones were collected from ticks (nymphs and adults)
 35 feeding on guinea pigs, at different points of the attachment period. The cones were homogenised in phosphate-buffered saline (PBS) to extract soluble proteins, and in hot alkali and acid to extract less soluble components (Kemp

et al., 1982; Jaworski et al., 1992).

Protein patterns were analysed using SDS-PAGE; the resulting gel is displayed as Figure 1A. Bands or spots corresponding with early expressed (group A) proteins and later expressed (group B) proteins were excised from the gel and used for the production of polyclonal antiserum. Good antisera could be obtained even against the less antigenic proteins provided that these proteins were not allowed to renature completely.

The resulting antisera were used to screen cDNA libraries and also for immunoblotting (see Figure 1B) and immunohistochemistry.

15

Proteins for which no good antiserum could be raised were blotted onto polyvinylidene difluoride membranes for amino-terminal sequence determination. For amino acid sequencing, samples were run on an Applied Biosystems 494A "Procise sequencer" (Perkin-Elmer, Applied Biosystems Division, Warrington U.K.). Electroblotted samples are run using Applied Biosystems "Mini-Blott" cartridge in the place of the standard cartridge. Bands of interest are excised from the membrane and cut into 1 x 3mm pieces for insertion into the cartridge. These are sequenced using the manufacturer's recommended programme for membrane-bound samples (Schagger and von Jagow, 1987; Matsudaira, 1987).

This information was then used to design oligonucleotides to screen a tick cDNA library for clones of interest.

Example 2 : cDNA library construction

Salivary glands were excised from 20 male and 20 female adult *R. appendiculatus* specimens that had been feeding on guinea pigs for two days. The glands were collected on dry ice in an Eppendorf tube. Messenger RNA was isolated using the FastTrack mRNA isolation kit (Invitrogen).

Prior to unidirectional insertion of the cDNA into the lambda vector, the nucleic acid was fractionated over a Sephacryl S-400 column (Pharmacia).

- 5 A library (termed d2-I) was constructed from low molecular weight cDNAs (ranging from approximately 100 to 2,000 base pairs). The higher molecular weight fraction was used to construct a second library (d2-II). Packaging was performed using Packagene (Promega) packaging extracts. Approximately
10 1.5×10^6 plaque-forming units (PFU) of each library were amplified in XL-1-Blue cells (Stratagene) for subsequent use.

Example 3 : Screening of the d2-II cDNA library

- 15 Phagemids were excised *in vivo* from a randomly selected fraction of the library, and used to generate double-stranded pBluescript SK(-) plasmids in XL1-Blue cells (Stratagene), as described by Short et al., (1988).

- 20 XL1-Blue colonies were plated out on ampicillin-containing LB (Luria-Bertani) agar plates, supplemented with 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-Gal, Melford Laboratories, UK) and isopropyl- β -D-thiogalactopyranoside
25 (IPTG, Novabiochem) for blue/white colony selection.

- About 75 plasmids (from white colonies) with inserts ranging from 250 to 1000 base pairs (as determined by digestion with PvuII and electrophoresis over a 1% agarose gel) were
30 selected for sequencing. The oligonucleotides used for sequencing correspond to the T3 and T7 primer sites in the pBluescript plasmid DNA.

Example 4 : Sequencing

- 35 Plasmids were purified from overnight cultures according to Goode and Feinstein (1992), alkali-denatured (Mierendorf and Pfeffer, 1987), and sequenced using the Sanger dideoxy-

Plasmids were purified from overnight cultures according to Goode and Feinstein (1992), alkali-denatured (Mierendorf and Pfeffer, 1987), and sequenced using the Sanger dideoxy-mediated chain termination reaction (Sanger and Coulson, 5 1975). Sequence data were analysed using the GCG sequence analysis software (Program Manual for the Wisconsin Package, 1994).

Protein database searches were performed at the National 10 Centre for Biotechnology Information (NCBI) using the BLAST network service (see Figures 2-8).

Example 5 : Production of the CemA Antiserum

15 An antiserum was produced against a prominent salivary gland protein of around 17kDa size.

For production of the polyclonal antiserum, salivary glands taken at day 6 of the adult feeding stage were homogenised 20 in phosphate-buffered saline (PBS), and submitted to centrifugation (3 min; 12,000 x g). The proteins in the supernatant [i.e. the salivary gland extract (SGE)] were resolved over a 15% SDS-polyacrylamide gel, according to Laemmli (1970).

25

The gel was stained in an ice-cold 100 mM KCl solution, and the 17 kDa protein was excised. The polyacrylamide section containing the protein was dried under vacuum, homogenised in PBS, mixed with an equal volume of Montanide ISA 50 30 adjuvant (Seppic, France) and subcutaneously injected into Dunkin Hartley guinea pigs. This procedure was repeated every 10 days. Serum was collected 10 days after the 4th injection.

35 Western blotting, performed according to Kyhse-Anderson (1984), showed a strong reaction of the antiserum with a 17kDa protein from the surface of cement cones (see Figure 1A). This protein, termed CemA, was present at all feeding

Example 6 : Immunohistochemistry/ western blotting/ northern blotting/ *in situ* hybridisation

5 The polyclonal antisera were used in western blots and in sections of cement cones and salivary glands, taken at different stages of the feeding period. Where light-microscopy did not provide sufficient resolution to visualise the stain, electron microscopy was used.

10

For proteins against which no antisera could be produced, northern blots were instead performed using digoxigenin-labelled DNA probes constructed by random primer labelling (Sambrook et al., 1989) using purified insert from the
15 original clones. An anti-digoxigenin antiserum conjugated with alkaline-phosphatase allows probe detection. In fact, *in situ* hybridisation may be more suitable for localising and following the expression of genes in the salivary glands, since immunohistochemistry when performed on
20 salivary glands often results in a high background.

In conjunction with the SDS-PAGE data, these techniques allow determination of the times at which specific proteins were expressed during the feeding period, where in the
25 salivary glands they were produced and to which layer of the cone they contribute (thus better defining group A and B proteins).

... **Example 7 : Construction of genomic libraries and**
30 **examination of differential expression.**

In order to evaluate the differential expression of tissue cement protein genes, the following procedure is presently being followed.

35

Genomic tick DNA, digested with suitable endonucleases is inserted into the Lambda Fix II vector (Stratagene), which allows for easy restriction mapping. Digoxigenin-labelled

cDNA probes are used for library screening.

Regions flanking the coding sequences and introns are being sequenced and examined for the presence of sites that might
5 play a role in the ordered expression of the proteins (for example ecdysteroid or heat-shock response elements). It was thought that comparison of genes of proteins expressed simultaneously might reveal common upstream or downstream sequences that are responsible for the regulation of gene
10 expression. All group A protein genes, for example, may have identical recognition sites for regulatory factors.

Prospective regulatory regions are coupled to a reporter gene, for example luciferase, transfected into suitable
15 cells (e.g. *Drosophila* cells), and submitted to functional assays. Gel retardation, DNA protection or band-shift assays are also being performed to confirm the existence of functional regulatory domains.

20 It is possible that a single promoter region controls the simultaneous expression of a whole series of genes. These genes are then most probably localised in close proximity to one another on the genome.

25 To investigate this possibility, the digoxigenin-labelled probes are being used to localise the genes on the genome by means of *in situ* hybridisation, Southern blotting and genomic library screening.

30 Expression of cement proteins may be regulated by one or more haemolymph-borne factor(s). This possibility is being investigated by incubating salivary glands taken from animals that have only just attached to their host in tissue culture medium containing haemolymph from ticks that have
35 been feeding for 24 or 48 hours. Blotting (northern and western) or reverse transcriptase-PCR is then used to determine whether genes have been switched on or off.

Where there is evidence for a haemolymph-borne factor controlling the expression of cement genes, transplantation of salivary glands from ticks early in the feeding stage, to animals later in the feeding stage is being carried out, in
5 case *in vitro* incubation experiments do not provide adequately clear results. This factor has been identified by HPLC and other standard techniques.

**Example 8 : Aggregation/ cross-linking studies - protein
10 expression**

Aggregation (polymerisation) and cross-linking are being determined using proteins extracted from salivary glands and cement cones, and also using expressed recombinant proteins.
15

Cement cone proteins are being examined directly by protein hydrolysis followed by detection of di- or tri-tyrosines among the amino-acids. Other assays are also being used for the detection of cross-linking enzymes and SDS-PAGE in the
20 presence and absence of reducing agents to reveal inter- or intramolecular disulphide-bridges.

In addition, native group A and B proteins are isolated from cement and salivary gland extracts by means of
25 immunoprecipitation. This is only possible for the more soluble proteins. The molecular weight of the precipitated proteins is being determined by gel filtration. Comparisons are being made to the molecular weight of monomers as determined .. by .. SDS-PAGE .. and .. western .. blotting, .. or .. as
30 calculated from the cDNA derived protein sequences.

Other components co-precipitating with a given (A or B) protein are being identified by screening the cDNA-library with oligonucleotide probes designed using N-terminal amino
35 acid sequences.

The nature of eventual intermolecular bonds are also being determined. Hydrogen-bonds can be destroyed with urea, and

hydrophobic interactions with detergents. Detection of disulphide-bridges and cross-linked amino-acids can be performed as described previously (Creighton, 1989; Malencik et al., 1996).

5

Studying native proteins is not always straightforward. For example, it can be difficult to extract enough protein to enable exhaustive study. Also, non-specific protein interactions may occur. Many of these problems can be solved
10 by the use of recombinant proteins in their place.

Recombinant (group A and B) proteins are therefore being expressed in bacteria or, where glycosylation and other post-translational modifications are crucial, in a
15 eukaryotic (baculoviral) system. Those proteins which are not very soluble can be expressed in fusion with thioredoxin using, for example, the ThioFusion system (Invitrogen).

In this system, the proteins are provided with
20 oligohistidine-tags, allowing easy purification by means of nickel-agarose chromatography (Janknecht et al., 1991). Enterokinase and/or thrombin sites are incorporated to remove tags and fused proteins from the cement protein after purification, in cases where this is necessary. In case
25 aggregation of a protein takes place, or if interaction occurs between, for example, two different group A proteins, the nature of the bonds must be determined, as for the native proteins - see above.

30 Expressed proteins which can be recognised at all times by their histidine tags, or by the antisera were incubated with salivary gland extracts, in the absence and presence of specific and non-specific enzyme-inhibitors, in order to identify cross-linking.

35

The histidine-tagged expressed proteins can then be coupled to nickel-agarose and used in affinity-chromatography (Bugge et al., 1992; Lu et al., 1993) to isolate interacting

proteins from salivary gland extracts or cement cones. These proteins can then be identified through the screening of cDNA libraries. By deletion and mutation experiments, domains or residues participating in the aggregation or
5 cross-linking of recombinant proteins, are thus being identified.

References

- Arthur D.R. (1951) *Parasitology* **41**, 66-81.
- 5 Brown S.J. and Askenase P.W. (1986) *Exp. Parasitol.* **62**, 40-50.
- Bugge T.H., Pohl J., Lonnoy O. and Stunnenberg H.G. (1992) *Embo J.* **11**, 1409-1418.
- 10 Creighton T., (1989) *Protein Structure - A practical approach*, IRL Press, 155-168.
- Davies F. (1988) In: Monath, T.P. (Ed.) *The Arboviruses: Epidemiology and Ecology*, CRC Press, Inc., Boca Raton, FL., 191-203.
- 15 Goode B.L. and Feinstein S.C. (1992) *Biotechniques* **12**(3), 374-375.
- 20 Ichinose A., Bottenus R.E. and Davie E.W. (1990) *J. Biol. Chem.* **265**, 13411-13414.
- Janknecht R., de Martynoff G., Lou J., Hipskind R.A., Nordheim A., and Stunnenberg H.G. (1991) *PNAS* **88**, 8972-8976.
- 25 Jaworski, D.C., Rosell R., Coons, L.B., and Needham G.R. (1992) *J. Med. Entomol.* **29**, 305-309.
- 30 Kemp D.H., Stone B.F. and Binnington K.C. (1982) In: Obenchain F.D. and Galun R. (Eds.) *Physiology of Ticks*. Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt, 119-68.
- 35 Kyhse-Anderson J. (1984) *J. Biochem. Biophys. Methods* **10**, 203-209.

Laemmli V.K. (1970) *Nature* **277**, 680-685.

Lu T., Van Dyke M. and Sawadogo M. (1993) *Anal. Biochem.* **213**, 318-322.

5

Malencik D.A., Sprouse J.F., Swanson C.A. and Anderson S.R. (1996) *Anal. Biochem.* **242**, 202-213.

Matsudaira P. (1987) *J. Biol. Chem.* **262**, 10035-10038.

10

Mierendorf R.C. and Pfeffer D. (1987) *Methods Enzymol.* **152**, 556-562.

Moorhouse D.E. and Tatchell R.J. (1966) *Parasitology* **56**,
15 623-632.

Norval R.A.I., Barrett J.C., Perry B.D. and Mukhebi, A.W. (1992) In: Fizas B., Petney T. and Horak I. (Eds.) *Tick Vector Biology - Medical and Veterinary Aspects*. Springer-
20 Verlag, Berlin Heidelberg.

Norval R.A.I., Perry B.D. and Young A.S. (1992) *The epidemiology of theileriosis in Africa*. Academic Press, London.

25

O'Reilly D.R., Miller L.K. and Luckow, V.A. (1994) *Baculovirus expression vectors - A laboratory manual*, Oxford University Press.

30 Sambrook et al., *Molecular Cloning: a Laboratory Manual: 2nd edition*, , 1989, Cold Spring Harbor Laboratory Press.

Sanger F. and Coulson A.R. (1975) *J. Mol. Biol.* **94(3)**, 441-448.

35

Schagger H. and von Jagow G. (1987) *Anal. Biochem.*, **166**, 368-379.

Shapiro S.Z., Voigt W.P., and Ellis J.A. (1989) *Exp. Appl. Acarol.* 7, 33-41.

Siegel R.C. (1979) *Int. Rev. Conn. Tissue Res.* 8, 73-118.

5

Sonenshine D.E. (1991) *Biology of Ticks*, Vol. 1. New York Oxford, Oxford Univ. Press., 447.

Sugumaran M., Giglio L, Kundzicz H., Saul S. and Semensi V.
10 (1992) *Arch. Insect. Biochem. Physiol.* 19, 271-283.

Walker A.R., Fletcher J.D. and Gill H.S. (1985) *Int. J. Parasitol.* 15, 81-100.

15 Watson J.D., Gilman M., Witkowski J and Zoller M. (1994)
Recombinant DNA (2nd edition), Scientific American Books.

CLAIMS

1. A tissue cement protein having the amino acid sequence shown in Figure 3 or Figure 7 or containing any one of the partial amino acid sequences shown in any one of Figures 2, 4 to 6 and 8, related tissue cement proteins from blood-feeding parasites, preferably ticks and functional equivalents thereof.
2. A tissue cement protein according to claim 1 that is of the group A subtype.
3. A tissue cement protein according to claim 1 that is of the group B subtype.
4. A tissue cement protein according to any preceding claim that binds to vertebrate tissues.
5. The tissue cement protein of any preceding claim that is derived from blood-feeding ectoparasites.
6. The tissue cement protein of claim 5 that is derived from ticks.
7. The tissue cement protein of claim 6 that is derived from Ixodid ticks.
8. The tissue cement protein of claim 7 that is derived from *Rhipicephalus appendiculatus*.
9. The tissue cement protein of any one of the preceding claims that is associated with one or more carbohydrate moieties.
10. The tissue cement protein of claim 9 that is associated with one or more glycosaminoglycan moieties.

11. The tissue cement protein of any one of the preceding claims that is expressed in recombinant form.
- 5 12. The tissue cement protein of any one of the preceding claims that is associated with one or more peptides or polypeptides.
- 10 13. The tissue cement protein according to claim 12 associated with one or more self molecules to form a homodimer, homotrimer or homotetramer unit.
- 15 14. The tissue cement protein according to claim 12 associated with one or more non-self molecules to form a heterodimer, heterotrimer or heterotetramer unit.
- 20 15. The tissue cement protein of any preceding claim that has been genetically or chemically fused to one or more peptides or polypeptides.
- 25 16. The tissue cement protein of any preceding claim that has been cross-linked to one or more peptides or polypeptides.
17. The tissue cement protein of any one of the preceding claims attached to a label.
18. The tissue cement protein of any one of the preceding claims attached to a toxin.
- 30 19. The tissue cement protein of any one of the preceding claims that is bound to a support, such as a resin.
- 35 20. A pharmaceutical composition comprising a tissue cement comprising a mixture of group A and group B tissue cement proteins according to any preceding

claim in the absence of other parasite saliva proteins but in the presence of one or more compounds capable of cross-linking said tissue cement proteins, in conjunction with a pharmaceutically-acceptable excipient.

21. A pharmaceutical composition comprising a tissue cement comprising a mixture of group A and group B tissue cement proteins according to any one of claims 1 to 19 in the absence of other parasite saliva proteins in conjunction with a pharmaceutically-acceptable excipient.
22. A pharmaceutical composition comprising a tissue cement comprising a mixture of group A and group B tissue cement proteins according to any one of claims 1 to 19 together with those saliva proteins necessary for the cement-hardening process, but in the absence of other parasite saliva proteins, in conjunction with a pharmaceutically-acceptable excipient.
23. The tissue cement protein according to any one of claims 1 to 19 or pharmaceutical composition of any of claims 20-22 for use in therapy.
24. The tissue cement protein according to any one of claims 1 to 19 for use as a pharmaceutical.
25. Use of the tissue cement protein according to any one of claims 1 to 19 as a pharmaceutical.
26. The tissue cement protein according to any one of claims 1 to 19 for use as a vaccine or as a component of a vaccine.
27. Use of a tissue cement protein according to any one of claims 1 to 19 as a vaccine or vaccine component.

28. A vaccine comprising a tissue cement protein according to any one of claims 1 to 19.
- 5 29. A method of production of the vaccine of claim 28 comprising immunising an animal with a tissue cement protein according to any one of claims 1 to 19.
- 10 30. A method of bonding animal tissue comprising bringing an animal tissue into conjunction with one or more tissue cement proteins according to any one of claims 1 to 19 that are capable of forming a hardened cement.
- 15 31. The tissue cement protein according to any one of claims 1 to 19 or pharmaceutical composition of any of claims 20-22 for use in the temporary or permanent bonding of tissues.
- 20 32. The tissue cement protein according to any one of claims 1 to 19 for use as protective immunogens in the control of diseases caused by infections transmitted by arthropod parasites.
- 25 33. A nucleic acid molecule which encodes a tissue cement protein according to any one of claims 1 to 19 or which hybridises with said nucleic acid molecule under standard hybridisation conditions.
- 30 34. The nucleic acid molecule of claim 33 which comprises DNA, cDNA or RNA.
- 35 35. The nucleic acid molecule of claim 33 or 34 which comprises DNA.
36. A cloning or expression vector comprising a nucleic acid molecule according to any one of claims 33 to 35.

37. The vector of claim 36 which is virus based.
38. The vector of claim 37 which is baculovirus based.
- 5 39. A host cell transformed or transfected with the vector of any one of claims 36 to 38.
- 10 40. A transgenic animal that has been transformed by a nucleic acid molecule according to any one of claims 33 to 35 or vector according to one of claims 36 to 38.
- 15 41. A method of preparing a tissue cement protein according to any one of claims 1 to 19, comprising expressing a vector according to any one of claims 36 to 38 in a host cell and culturing said host cell under conditions where said protein is expressed, and recovering said protein thus expressed.
- 20

THIS PAGE BLANK (USPTO)

FIG. 1B





FIG. 1A



A B C D



THIS PAGE BLANK (USPTO)

FIG. 2

1 AAACCAAGGCAGGACACAGCAGCCATGAAGGCCCTTCGTTGCAGTCGCCCTTTTGTCTGCA 60

M K A F V A V A L L S A

61 GTTTC CGTGGCACATGCTGCCCTCAAGACTGACGTAGCCAGTGGACCTGCCGGTTCTGGT 120
V S V A H A A L K T D V A S G P A G S G

2/11

121 GCACTAAGTCTAGGAGTTGGAGGCTTCCCGTCCGGTGCTTCGCTTGGCAGCCTTAGTGGC 180
A L S L G V G G F P S G A S L G S L S G

181 GTAACCCCTCTGGTGCTGGCTCTTCCCGTGTCTGGCCGCCCTGGATCCCCTGGATCGGCT 240
V T L S G A G S S V S G R P G S P G S A

241 GGTCCCTAGCTCTGGACCCGCA GTGCG 267
G P S S G P A V S

THIS PAGE BLANK (USPTO)

FIG. 3

1 CGGACGCACACTCCTGCAGGAAGGTCATCTAGTTCGCGCCAACATGAAGCTGCTCTGTGCA 60
M K L L C A

61 CTAGCCCTCGTTGCCCTTGGAATTCCATTTCGGCAGCGCTTACCTTGGTGGCTTCGGCGGC 120
L A L V A L G L P F G S A Y L G G F G G

121 CTCGGTGGTTGGGGTGGCGGTCTCGGTGCCATCTTTGGCCAGGAGCTTATCCCGGTTTC 180
L G G W G G G L G A I F G P G A Y P G F

181 TATGGCCTTAACACAGCGTGCACCTCTTGGGCGCAGGTTCCACCATCTCTTCGGGCGATTTC 240
Y G L N S V H L L G G R F H H L F G R F

241 CCGCCACCAACCGGTATTGGAGCTGCTGAAGCGCAGGGGAACCTAAGCCCATACCCCTCTT 300
P P P G I G A A E A Q G N L S P Y P L

301 GACATCAACACCGTCCAAGACCCGAACTGGCCACCCCATGTACGCGTTGTCTACGGCGG 360
D I N T V Q D P N W P P H G T R C L R R

361 AGTCTTGGGGAGCGCCTCTGACCCTGACCAGTCCCAATTCCACAGGATGTGCCTGTCCC 420
S L A G A P L T L T S P N S T G C A C P

THIS PAGE BLANK (USPTO)

421 AGTCCCCATTCCAGTGCCCCAGCCATACCCAGTCCACACCCACGACAAGTTCATACCC 480
S P H S S A P A I P S P T P T S S I P

481 AGTGCCTAGTCCCTACCCCGTCCCAATCCACAGTAACACCGAAGTTCACAAGACCGACGT 540
S A

4 / 11

541 CGTCGCCGCTACTCCAGGAGGACCAGTCCCTGCTCGGAGTCGGTGTCAACCGGTGCAGGCC 600

601 AGGCGAACCAAGGTCGTGGCCCTAAGCTTGATCCAATAGAAAGTCATAACAATTAGTCA 660

661 GTGAGCTCCACGTAATTATGCATTACAAATAAAGAAAAGTTGTCTGGCAGTAAAAAAA 720

721 AAAAAAAAAA 730

FIG. 3(CONTD.)

THIS PAGE BLANK (USPTO)

FIG. 4

1 GATCGGCACGAGGTCAAGGGAGCCCTCCTTCAGCAACAACAGCATCGCAGGTTAAGGGA 60
D R H E V K G A L L Q Q Q A S Q V K G

61 GCCCTCAAGGGAGCAATCAAGGGTGGTCTTCTTCAGCAACAAGCCCCAATCCCCAAGTCCAA 120
A L K G A I K G G L L Q Q Q A Q S Q V Q

121 GGAGCTCTTAAGGGAGCCGTCAAGGGAGCCCTCCTTCAGCAACAACAGGCATCACAGGTC 180
G A L K G A V K G A L L Q Q Q Q A S Q V

181 AAGGGAGCCCTCAAGGGAGCCCATCAAGGTCTGTCTCCTTCATCAGCAAGCCCAATCCCCAA 240
K G A L K G A I K V C L L H Q Q A Q S Q

241 TCCCAAGTTCAGGGAGCTCTTAAGGGAGCTG 271
S Q V Q G A L K G A

THIS PAGE BLANK (USPTO)

FIG. 5

1 GGAAGTAGCGAGCATCCGCACTGGGGTCTTTTGGCTGCATTTGCTTTCTTCTTCAGC 60
E V A S I R T G V F L A A F A F L L S A

61 GATCCATAACAATGGCCAGTCATGTGTAGATGCAGCCCCCACTCGACGTCTATGCCATC 120
I H N N G Q S C V D A A P T R R P M P S

121 TCCTCCTGGATGTGCTGGTCCTGGCTGTTTACTGGTATTGCTACTCTTCTAAGACCTGG 180
P P G C A G P G C F T G I A T L L R P G

181 TCAAGGACAGCAACCTGGTCAAGGACAGCAACCTGGTCAAGGGCGTCTCCAATGCCACG 240
Q G Q Q P G Q G Q Q P G Q G R P P M P R

241 TCCAGGACCTGTTCCAGGAACATCTGGATCACCTCAAGGAAGACCCCAATGGAGCACCTCG 300
P G P V P G T S G S P Q G R P N G A P R

301 TCCAGGACCTGTTCTGGAAACATCTGGATCACCTCAAGGAAGACCTAACGCAAGACCTCG 360
P G P V P G T S G S P Q G R P N A R P R

361 TCCAGGACCTGTTCTGGAAACACCAACTGTATCCTCTCCCGGATCATCTCCTGGTCATC 420
P G P V P G T P T V S S P G S S P G S S

THIS PAGE BLANK (USPTO)

421 TCCAGGAATATCTAGGAACGCCCTCTAGGAACACCTCTAGGAACACCTCAAGGATCACC 480
P G I S L G T P L G T P L G T P Q G S P

481 TTTTGGATCATCTCTTGGATCATCGATAGGATCACCTCCTGCAACATCTCCTGGATCATC 540
F G S S L G S S I G S P P A T S P G S S

541 TTCTCCGTCACCTCCTGGATCAGCGAATGTGAACCTGCTGGGTCTCGACCAATTCCGCGG 600
S P S P P G S A N V N L L G P R P I R G

601 TCCTGGAAGGCATTGACGGGACCAGTTCTGCTGTGTATTCTCCGTGCACAAATGAGGGAA 660
P G R H

661 GGCAATTGATGGGACCAGTTCTGCTGTGTATTCTCCGTGCACAGTGAGGGAATCTATCAA 720

721 TAGTGCAATAA 731 **FIG. 5(CONTD.)**

THIS PAGE BLANK (USPTO)

1	GGCTTCGGCAGCCCACTCAGCGGTTTCGGCAGCCCACTCAGCGGTTTCGGCAGCCCACTC	60
	G F G S P L S G F G S P L S G F G S P L	
61	AGCGGCTTCGGCAGCCCACTCAGCGGATTTCGGTAGCCCACTCAGCGGATTTCGGTAGCCCA	120
	<u>S G F G S P L S G F G S P L S G F G S P</u>	
121	CTCAGCGGATTTCGGTAGCCCACTTCGGCAGCTACGGTCCCCTGTCCATGGGTCTCGGAGCC	180
	<u>L S G F G S P F G S Y G P L S M G L G A</u>	
181	CCCAGGAGATTCCC CGGACCTCCGCTCATCTCTGAGCCCACTCCCGCCTTCCC GTT	240
	P R R F P G D L R L I S E P T S R L P V	8/11
241	AGCGATGCCGTCTACACCGCTGTCGTCCAGCCCCGTCAAGCGCAGTGGTCCACACCGAG	300
	S D A V Y T A V V Q P V T S A V V H T E	
301	GGTCCCCATGTCACCGGCCAAGTACAGGAACACGTTGCAATCTAAGCTTTTCTAACCGCA	360
	G P H V T G Q V Q E H V A I	
361	AGCTATATTACGACGGATTAGTCAACACAGTCATCTTAAGCAAATGTATCTAAATAAAA	420
421	TTTATCTGCCT	431

FIG. 6

THIS PAGE BLANK (USPTO)

FIG. 7

9/11

1	GGAGATCACCTGCTTGCAAGGACAACGTCCTTAACACAGCCGCAAAATGAAAGCTTCTT	60
	M K A F F	
61	CGTTCTTCCCTTCTTCAACCGCGCACTGACGAATGCAGCAAGGGCTGGTCGTCTTGG	120
	V L S L L S T A A L T N A A R A G R L G	
121	AAGCGACCTGGATACATTGGAAGGGTACACGGTAACCTATATGCCGGCATCGAAAGAGC	180
	S D L D T F G R V H G N L Y A G I E R A	
181	TGGCCCTCGTGGATACCCAGGGCTTACCGCATCGATTGGAGCGAAGTGGTGCACGACT	240
	G P R G Y P G L T A S I G G E V G A R L	
241	CGGTGTCGTGCCGGTGTGGAGTGAGCAGCTACGGCTATGGTTACCCCTTCATGGGGCTA	300
	G G R A G V G V S S Y G Y G Y P S W G Y	
301	TCCGTATGGTGGATACGGTGGATACGGTGGATACGGTGGATATGATCAGGG	360
	P Y G G Y G G Y G G Y G G Y D Q G	

THIS PAGE BLANK (USPTO)

361 TTTTGGCTCTGCATACGGCGGGCTACCCCGGCTACTATGGCTACTACTATCCCAGTGGCTA 420
F G S A Y G G Y P G Y Y G Y Y Y P S G Y

421 CGGTGGGGGCTACGGTGGTAGCTACGGTGGCAGCTACGGTGGTAGCTACACCTATCCCAA 480
G G Y G G S Y G G S Y G G S Y T Y P N

481 CGTTCGGGGCTTCAGCTGGTGCCGAGCTTGAGCTTCTCCTTCAGCGTCACAGTAAGAAAT 540
V R A S A G A A *

541 CATGGAGCACCCGATCGAGAAATACAGAGGTTCTCAAAGCGTACGGGATGCCAACCCAGC 600

601 AAGAAATTGCGCCGCAAAATGTTGAGAACAAATACAAGTTTCTGTAAAAAATAAAA 656

FIG. 7(CONTD.)

THIS PAGE BLANK (USPTO)

FIG. 8

1 ACGGACTAGGTTTCGCTGGCGTCCCTCTTATTGGCGGATACGGCTACGGTCCTTTCGTAG 60
G L G F A G V P L I G G Y G Y G P F V G

61 GAGCCTTCGCGTACGGCTTGTTGGGGTGGCCTCGGTGGCTATGGCTACCCCTGCCTTCGGAC 120
A F A Y G L W G G L G G Y G Y P A F G L

121 TCTCCTGGGTTCCACATGGTTTGGAGGCTTTGGAGCTTCTCCGCTGCTGCTGGTTTCC 180
S W V P H G F G G F G A S P S A A G F R

181 GCTCGCTTTGGAGCCTCTT 199
S L W S L

11/11

FIG. 9

R.appendiculatus

GLGFAGVPLIGGYGYPFVGAFAAYGLWGLGGYGYPAFGLSWVPHGFGFGASP
|. |: |.. :| | | | | : | : : | | : | : : | | : | : : | : : | : :
GYGY.GAKKVGGYGYGAKLGGYGYG..AKIGGYGYGAKSGIQV.RALGGYGAGA

P.californica

PCT/GB98/03397

12.11.98

Carpmael & Ransford

9723945.3

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)